Our Development Programs
Kanna Health is developing KH-001, a unique proprietary form of a naturally-occurring alkaloid, for the treatment of premature ejaculation (PE).
Premature ejaculation (PE) is a distressing condition in which men ejaculate too quickly before or shortly after vaginal penetration (often within less than a minute). There are currently no treatments approved by the FDA, despite the condition affecting up to 20% of men. These men report lower levels of sexual functioning and satisfaction, decreased self-esteem, and higher levels of personal distress. Partners of these men also suffer, and report sexual dissatisfaction and frustration, as well as problems in the relationship.
KH-001 has shown promising results in proof-of-concept animal studies and is set to enter the clinic in 2023.
Kanna Health is developing a proprietary library of kanna-inspired new chemical entities (NCEs) whose pharmacological and pharmacokinetic properties can be fine-tuned to target a range of high unmet need neuropsychiatric disorders.
Check out this space for development updates.
Undisclosed discovery program